What does this research mean for the field?

Smaller and shorter early-phase trials for chronic hepatitis B are more likely to complete, while novel trial designs do not lead to faster completion. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aims to analyze how different trial designs affect the performance and completion of clinical trials for curing chronic hepatitis B.

March 16, 2026

Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance

Puntos clave

The research aims to analyze how different trial designs affect the performance and completion of clinical trials for curing chronic hepatitis B.
Compared characteristics of trial designs with completion rates
Analyzed early-phase trials in relation to size and duration
Evaluated outcomes related to direct-acting antivirals
Smaller and shorter early-phase trials are more likely to complete
Novel trial designs do not correlate with faster completion
Direct-acting antivirals lead to significant HBsAg decline but do not guarantee a durable functional cure

Resumen

Smaller and shorter early-phase trials were more likely to complete, whereas novel trial designs were not associated with faster completion. Direct-acting antivirals showed marked end-of-treatment HBsAg decline, an on-treatment signal rather than durable functional cure.

Me gusta

Guardar

Cite This Study

Shi et al. (Fri,) studied this question.

synapsesocial.com/papers/69b79e6e8166e15b153abb4d https://doi.org/https://doi.org/10.1111/jgh.70346

Me gusta

Guardar